Saturday 17 October 2026
Export DERM’s income statement to Excel — free account
Journey Medical Corporation
DERM Healthcare Drug Manufacturers Specialty & Generic
Journey Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $61.9 million, up 10.2% from fiscal 2024. In the quarter to June 2026, revenue grew 23.3%, EPS grew 93.8%, free cash flow fell 84.1% and total debt rose 1.43%, each against the same quarter a year earlier.
4.97
0.16
−3.12%
Follow DERM
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 2 | 7 | 3 | 3 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
1.09 | (0.39) | 0.97 | (0.72) | (0.09) | — | — | — |
P/S ratio |
3.05 | 1.42 | 1.25 | 0.44 | 0.87 | 1.65 | 1.65 | — |
P/FCF ratio |
0.00 | 0.00 | 412.50 | 0.00 | 0.00 | 14.92 | 14.92 | — |
Altman Z″-Score (non-manufacturers) |
(1.40) | (3.27) | (1.63) | (3.00) | (0.70) | 2.51 | 1.97 | — |
Beneish M-Score |
(0.82) | (3.10) | (3.43) | (3.28) | (4.23) | (2.14) | — | — |
P/Operating CF |
(30.06) | 35.90 | (5.99) | (8.41) | (17.10) | 12.77 | 12.77 | — |
P/B ratio |
5.93 | 3.98 | 4.86 | 1.90 | 1.30 | 0.00 | 0.00 | — |
Price to Tangible BV |
44.47 | 0.00 | 1,571.42 | 0.00 | 1.86 | 0.00 | 0.00 | — |
EV/Sales |
3.16 | 1.56 | 1.13 | 0.31 | 0.16 | 1.61 | 1.61 | — |
EV/EBITDA |
0.00 | 0.00 | 17.19 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(15.73) | (9.59) | 17.04 | (1.70) | (4.67) | 14.56 | 14.56 | — |
EV/FCF |
(7.13) | (3.63) | 372.00 | (0.69) | (0.77) | 14.56 | 14.56 | — |
Quick Ratio |
1.44 | 0.87 | 1.02 | 0.90 | 1.40 | 1.15 | 1.14 | — |
Current Ratio |
1.79 | 1.37 | 1.35 | 1.16 | 1.64 | 1.26 | 1.21 | — |
Net Debt/EBITDA |
(0.35) | (0.46) | (2.47) | 0.40 | 1.50 | 0.17 | 0.08 | — |
Debt/Assets |
26.72% | 31.01% | 19.03% | 21.66% | 4.56% | 18.93% | 15.66% | 0.00% |
Debt/Equity |
0.79 | 1.24 | 0.72 | 1.34 | 0.11 | 0.95 | 1.93 | — |
Asset Turnover |
0.71 | 0.71 | 0.87 | 0.73 | 0.85 | 1.04 | 2.06 | — |
Operating CF/Net income |
1.09 | 0.62 | (1.36) | 0.46 | 0.05 | 0.97 | 2.49 | — |
Capex/Depreciation |
0.00 | (3.92) | (0.69) | (4.52) | (1.95) | (0.79) | (1.90) | — |
Interest Coverage |
(2.21) | (5.07) | (1.22) | (13.63) | (4.96) | 11.25 | 20.62 | — |
| (44.03%) | (72.60%) | (20.64%) | (100.39%) | (168.12%) | 81.00% | 55.58% | — | |
| (13.08%) | (18.68%) | (4.23%) | (29.27%) | (58.98%) | 12.32% | 21.41% | — | |
ROIC |
(15.46%) | (34.69%) | (17.20%) | (221.83%) | 0.00% | 41.33% | 101.01% | — |
Return on Tangible Assets |
(38.84%) | (112.83%) | (26.41%) | (273.14%) | (133.81%) | 73.57% | 82.84% | — |
Average Days of Receivables |
175.74 | 66.53 | 70.17 | 139.76 | 133.62 | 196.13 | 198.12 | — |
Research and Development Expense of Revenue |
0.78% | 17.56% | 9.52% | 14.85% | 26.23% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
71.73% | 71.62% | 55.46% | 80.72% | 63.09% | 49.60% | 54.78% | — |
Intangible Assets out of Total Assets |
0.29 | 0.40 | 0.26 | 0.26 | 0.13 | 0.29 | 0.22 | 0.00 |
Share Based Compensation of Revenue |
10.17% | 10.86% | 3.29% | 6.01% | 3.91% | 0.34% | 0.69% | — |
Graham Net Nets |
0.02 | (0.15) | 0.00 | (0.33) | 0.53 | (0.37) | (0.37) | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(6.10%) | (18.93%) | (4.42%) | (91.30%) | (75.66%) | (24.52%) | (24.52%) | — |
Free Cash Flow Yield |
(14.53%) | (30.20%) | 0.24% | (103.96%) | (24.04%) | 6.70% | 6.70% | — |
Revenue per Share |
2.53 | 2.75 | 4.34 | 4.20 | 6.20 | 4.87 | 3.82 | — |
Operating CF per Share |
(0.51) | (0.45) | 0.29 | (0.77) | (0.21) | 0.56 | 0.99 | — |
Capex per Share |
0.00 | (0.73) | (0.27) | (1.14) | (0.98) | (0.13) | (0.26) | — |
Free Cash Flow per Share |
(0.51) | (1.18) | 0.01 | (1.91) | (1.20) | 0.43 | 0.72 | — |
Cash per Share |
0.98 | 0.99 | 1.51 | 1.83 | 4.82 | 0.90 | 0.53 | — |
Shareholders Equity per Share |
1.30 | 0.98 | 1.12 | 0.97 | 4.13 | 1.13 | 0.30 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.30 | 0.98 | 1.12 | 0.97 | 4.13 | 1.13 | 0.30 | — |
Free Cash Flow |
(12.44) | (24.13) | 0.24 | (33.53) | (12.18) | 3.93 | 6.62 | — |
Working Capital |
29.43 | 13.00 | 14.59 | 10.85 | 32.88 | 7.18 | 4.37 | — |
Capital Expenditures |
0.00 | (15.00) | (5.00) | (20.00) | (10.00) | (1.20) | (2.40) | — |
Net Current Asset Value |
4.14 | (11.99) | (0.04) | (10.50) | 29.25 | (6.37) | (5.84) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.27 | 0.06 | 0.27 | 0.16 | 0.03 | 0.07 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 252.80 | — |
Cash ROIC |
(15.32%) | (36.97%) | 0.38% | (46.73%) | (12.75%) | 13.86% | 51.48% | — |
Accounts Receivable Turnover |
3.09 | 4.41 | 3.65 | 2.87 | 2.68 | 2.08 | 1.63 | — |
Accounts Payable Turnover |
1.68 | 1.21 | 0.83 | 1.02 | 2.53 | 7.18 | 5.18 | — |
Inventory Turnover |
1.74 | 1.69 | 1.88 | 2.56 | 5.70 | 12.91 | 9.32 | — |
Average Days of Payables |
154.40 | 280.58 | 292.47 | 438.63 | 266.81 | 48.92 | 73.06 | — |
Days of Inventory on Hand |
167.88 | 252.28 | 162.72 | 167.93 | 112.19 | 35.11 | 29.70 | — |
Average Receivables |
20.01 | 12.73 | 21.72 | 25.66 | 23.52 | 21.44 | 21.44 | — |
Average Payables |
12.45 | 17.20 | 27.66 | 30.22 | 12.70 | 2.03 | 2.03 | — |
Average Inventory |
12.03 | 12.32 | 12.18 | 12.01 | 5.63 | 1.13 | 1.13 | — |
Average Assets |
87.42 | 78.55 | 91.00 | 101.22 | 74.60 | 42.88 | 16.93 | — |
Average Common Equity |
25.96 | 20.21 | 18.67 | 29.51 | 26.17 | 6.52 | 6.52 | — |
Columns are period end dates